Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The report, "Synthetic ... Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene ... Biomaterials, Bioremediation) - Global Forecast to 2018", ... threats, opportunities, and challenges. , Browse 99 ... through 185 pages and in-depth TOC of ...
(Date:11/21/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the Sodium ferrocyanide ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... and CEO Marc Hedrick , M.D. will present live ... Thursday, December 4, 2014 TIME:    11:15 am PT ... or paste this URL into your browser,s address bar: ... to save time and receive event updates. ...
(Date:11/18/2014)... Cirrascale Corporation ®, a ... rackmount computing infrastructure, today announced it will offer ... its GPU-enabled blade server and high-performance workstation product ... proprietary 80-lane Gen3 PCIe switch-enabled risers, the GB5400 ... dual-GPU accelerator cards in a single blade, allowing ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... Co., Ltd., and its parent company, Otsuka Holdings Co., ... for Human Use (CHMP), a division of the European ... of Teysuno™ (S-1), a novel oral anti-cancer agent, intended ... when given in combination with cisplatin. The Committee will ...
... Catal de Nanotecnologia (ICN), in Barcelona, has demonstrated a device ... key step in developing the spin computers of the future. ... the journal Science. The authors are Marius V. Costache and ... the Physics and Engineering of Nanodevices Group at ICN. ...
... Quest Diagnostics (NYSE: DGX ), the ... services, today announced that its Care360™ Electronic Health ... was certified as a Complete EHR on Wednesday, ... eligible Health Information Technology (CCHIT®), an ONC-ATCB, in ...
Cached Biology Technology:Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer 2Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer 3Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer 4A 'spin ratchet': A new electronic structure for generating spin current 2Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification 2Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification 3Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification 4
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/15/2014)... we may still be a few years away from the ... gain instant access to all that ailed his patients, mobile ... for monitoring and measuring our health are cropping up in ... tad Orwellian to some, but a new survey suggests that ... into their healthcare regime. These are some of ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... at the University of North Carolina at Chapel Hill have ... programmed cell death or apoptosis. This molecule, a tiny ... shown to be in short supply in certain neurodegenerative illnesses ... could herald a new treatment to prompt brain cells to ...
... lower total and LDL (low-density lipoprotein or "the ... mechanism whereby soy protein lowers cholesterol remains unresolved. ... of Clinical Lipidology last month shows that ... lipoprotein) cholesterol significantly more than milk protein in ...
... even though their close relatives rays and chimaeras have ... Nathan Scott Hart and colleagues from the University of ... Their study shows that although the eyes of sharks ... only have a single long-wavelength-sensitive cone* type in the ...
Cached Biology News:New molecule could save brain cells from neurodegeneration, stroke 2New molecule could save brain cells from neurodegeneration, stroke 3New study shows soy protein lowers non-HDL cholesterol significantly more than milk protein 2Are sharks color blind? 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Biology Products: